All News

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Pharmacists are ranked as one of the top most-trusted professions, but what happens when they make mistakes?

With the smart tablets coming to market in 2018, it is a good time to explore how the technology behind the product works.

The holiday presents a great opportunity for pharmacists to help educate patients.

Here are ways for pharmacists to relieve foot and leg aches after a long shift.

A team of researchers have assessed supertherapeutic doses of NSAIDs, opioids, and benzodiazepines.

Sunitinib malate (Sutent) is an adjuvant therapy for adults at risk of recurrent renal cell carcinoma following nephrectomy.

Sunitinib malate (Sutent) may improve disease-free survival among patients with renal cell carcinoma.

Officials with the FDA have approved emicizumab-kxwh (Hemlibra, Genentech) as a treatment for patients with hemophilia A who have factor VIII inhibitors, according to a press release from the agency.

Officials with the FDA have approved obinutuzumab (Gazyva, Genentech) in combination with chemotherapy, followed by obinutuzumab alone, for the first-line treatment of patients with advanced follicular lymphoma, according to the company's press release.

Emicizumab-kxwh is administered as a weekly subcutaneous injection to restore clotting ability in patients with hemophilia.

Emicizumab-kxwh (Hemlibra) demonstrated the ability to reduce bleeding events that require treatment in patients with hemophilia A.

Fulvestrant (Faslodex) plus abemaciclib may improve progression-free survival among patients with advanced or metastatic breast cancer.

In this clip taken at the 2017 American Heart Association Meeting, Robert Carey, MD, of the University of Virginia discusses the expected increases in the population from the 2003 and 2017 guideline recommendations on hypertension.

Benralizumab is a monoclonal antibody that causes natural killer immune cells to reduce eosinophils.

Benralizumab (Fasenra) demonstrates the ability to significantly deplete eosinophils and could reduce the need for oral steroid use.

The NSS-2 Bridge device reduced opioid withdrawal symptoms more than 31% within 30 minutes of treatment.

Febuxostat (Uloric) could escalate heart-related and all-cause mortality.

Fallopian tube lesions may be the precursor to high-grade serious ovarian carcinoma.

Numerous immune cells may be involved with type 2 diabetes, according to a session presented at the at the American College of Rheumatology Annual Meeting.

Fully understanding a patient's genes may help physicians treat rheumatic diseases.

The 2016/2017 H3N2 influenza vaccine was only 30% effective, leaving many vulnerable to infection.

Health care stakeholders need to do a better job of adjusting testing and treatment to follow the HIV epidemic.

Patients who engage in lifestyle changes can effectively prevent or at least delay a lifelong, chronic disease.

Top news of the day from across the healthcare landscape.

Speeding up the review of drugs to treat serious diseases makes sense. Here is a look at how it works.

Here is a cheat sheet of the most common prescription drugs for canines.

Top news of the day from across the healthcare landscape.

What role does this medication play in diabetes therapy, and what are its clinical benefits, compared with competitors?